NCT00043758已完成2 期
Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients
Otsuka Pharmaceutical Development & Commercialization, Inc.40 个研究点 分布在 2 个国家目标入组 170 人开始时间: 2002年7月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 170
- 试验地点
- 40
研究概览
简要总结
The purpose of this study is to study the effects of tolvaptan on the size and function of the left heart chamber (ventricle) in patients with congestive heart failure (CHF)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •History of congestive heart failure
排除标准
- 未提供
研究者
研究点 (40)
Loading locations...
相似试验
已完成
3 期
"SALT Trial" Study of Ascending Levels of Tolvaptan in HyponatremiaHyponatremiasInappropriate ADH SyndromeWater-Electrolyte ImbalancesWater IntoxicationNCT00072683Otsuka Pharmaceutical Development & Commercialization, Inc.205
已完成
3 期
Study of Ascending Levels of Tolvaptan in HyponatremiaInappropriate ADH SyndromeWater-electrolyte ImbalanceHyponatremiaWater IntoxicationNCT00201994Otsuka Pharmaceutical Development & Commercialization, Inc.243
已完成
3 期
Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)Polycystic Kidney Disease, Autosomal DominantNCT00428948Otsuka Pharmaceutical Development & Commercialization, Inc.1,445
已完成
2 期
8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)Autosomal Dominant Polycystic Kidney DiseaseNCT01451827Otsuka Pharmaceutical Development & Commercialization, Inc.178
撤回
3 期
A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic HyponatremiaHyponatremiaNCT02442674Otsuka Pharmaceutical Development & Commercialization, Inc.